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Abstract
We report a case of an infant who experienced exogenous re-infection of Streptococcus pneumoniae
serotype 14 as a cause of recurrent meningitis after apparently successful antibiotic treatment with
ceftriaxone. eBURST analysis revealed that isolates from the two episodes of meningitis belonged
to hypervirulent ST63 and ST3321 clonal complexes respectively.
Background
Pneumococcal meningitis is common within the African
meningitis belt and occurs in a seasonal pattern indistin-
guishable from that of meningococcal meningitis [1].
Streptococcus pneumoniae can be subdivided by serological
typing based on the capsular polysaccharide protein into
at least 91 different serotypes [2] the majority of which
rarely cause disease. S. pneumoniae serotype14 is a com-
mon cause of severe pneumococcal disease in The Gambia
and ranks first among 127 pediatric invasive isolates
recently tested during a 9-valent pneumococcal conjugate
vaccine trial in The Gambia [3]. S. pneumoniae serotype14
has also been associated with meningitis outbreaks in
Ghana [4] and Niger [5]. The World Health Organisation
recommends the use of the 7-valent pneumococcal conju-
gate vaccine [6] which contains serotype 14, but this is not
yet available for routine use in Africa including The Gam-
bia. Multilocus sequence typing (MLST) is a well-estab-
lished method that has been used to assess the population
structure of S. pneumoniae during vaccine studies in The
Gambia [3]. This report describes the use of MLST to dem-
onstrate exogenous re-infection as a cause of recurrent
meningitis in a child from The Gambia.
Case report
A six months old female of the Manjago tribe, from a peri-
urban coastal village in The Gambia was referred from a
primary health care facility and admitted to the Royal Vic-
toria Teaching Hospital, Banjul on 6th December 2007
with clinical signs suggestive of meningitis. This diagnosis
was confirmed by microscopic examination of the cere-
brospinal fluid (CSF), which revealed gram-positive cocci
and leucocytosis. The child was clinically successfully
treated with intravenous ceftriaxone (100 mg/kg body
weight daily for 13 days), during which S. pneumoniae was
isolated from the CSF, subsequently identified as serotype
14 using methods described previously [7]. No neurolog-
ical sequelae were evident after this episode. On 3rd Janu-
ary 2008, the same child was re-admitted to the Medical
Research Council Laboratories Hospital, Fajara again with
clinical signs suggestive of meningitis. Similarly, this diag-
nosis was confirmed by microscopic examination of the
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CSF, which revealed gram-positive cocci and leucocytosis.
Both CSF and blood culture from the second episode grew
S. pneumoniae later confirmed as serotype 14. The second
episode was treated without recurrence using intravenous
chloramphenicol (25 mg/kg/dose) and crystalline penicil-
lin (100,000 i.u/kg/dose) both 6 hourly for 14 days. Sadly
the child had obvious neurological sequelae from the sec-
ond episode.
The MRC microbiology laboratory submits to the external
quality assurance programme of the United Kingdom
National External Quality Assessment Service [8].
Discussion
The fact that the serotyping results for S. pneumoniae were
identical for the two episodes of meningitis was suggestive
of endogenous (same isolate) reactivation due to failure
of antibiotic treatment. The E-test MIC antibiotic suscep-
tibility profile of the pre-treatment isolate from the first
episode was sensitive to tetracycline and penicillin G
whereas the two isolates from the pre-treatment second
episode were both resistant to these antibiotics (table 1).
Subsequent infection with more resistant organism may
represent changes in the susceptibility of colonizing
organism as a result of antibiotic therapy because carriage
of S. pneumoniae serotype 14 is common in The Gambia
[9]. Seemingly, S. pneumoniae carriage may provide a set-
ting for selection of more resistant strains as well as pro-
viding continuing endogenous source of infection. To
investigate this hypothesis, pneumococcal strain typing
by BOX-PCR and MLST was performed as previously
described [3] on the three isolates collected during the
two episodes of meningitis. Sequence types (STs) were
analyzed for relatedness using the eBURST v3 program
[10]. MLST analysis showed that the pneumococcus iso-
lated during the first episode of meningitis belonged to
ST915 previously shown to be present in The Gambia
[11]. However, MLST analysis from the pneumococci iso-
lated from both blood and CSF during the second episode
of meningitis were novel, i.e. not found in the S. pneumo-
niae MLST database [11]. An eBURST [10] analysis that
included the STs from this study and its single variant
locus (SVL) available in the MLST database [11] was per-
formed using the stringent 6/7 identical loci definition.
eBURST groups these STs into two major (ST63 and 3321)
clonal complexes indicating that these two isolates are
unrelated (figure 1).
Serotype 14 is covered by both the 7-valent and 9-valent
pneumococcal conjugate vaccines (Wyeth). However,
during the efficacy trial in The Gambia, three of the chil-
dren who received three doses of the 9-valent pneumococ-
cal conjugate vaccine were infected with serotype 14 of ST
63, ST 3320 and ST 3333 [3]. In this study, the first epi-
sode of meningitis was caused by serotype 14 of ST915; a
clone previously described in carriage from The Gambia
and is a single-locus variant (SLV) to the ST3318 clonal
complex which has so far only been reported from The
Gambia [3]. The second episode was due to a novel ST
(unassigned), which is a SLV to the hypervirulent ST63.
The ST63 clonal complex has caused cases of meningitis in
Northern Ghana and Niger [4,5]. However in The Gam-
bia, ST63 is common in cases of pneumonia and bacterae-
mia [3]. Furthermore, ST63 can also express serotypes
15A, 19A, 19F and 23F [11] indicating it propensity to
switch serotypes. The two clones (ST915 and unassigned
ST) recovered from both episodes of meningitis shared no
alleles and BOX-PCR fingerprinting analysis revealed dis-
tinct profiles indicating that these are unrelated clones
(figures 1 and 2).
Despite in vitro resistance to tetracycline and penicillin G,
both episodes of meningitis were successfully treated with
regimens that include intravenous ceftriaxone (first epi-
sode) and crystalline penicillin and chloramphenicol
(second episode). It is encouraging that in The Gambia,
pneumococcal isolates are still sensitive to chloramphen-
icol, which remains a first line treatment for severe pneu-
monia, septicaemia and meningitis locally and is more
affordable than cefotaxime or ciprofloxacin. Recurrent
infections caused by organisms of the same species, some-
times with identical antibiotic susceptibility patterns are
often regarded as relapse of persistent, unclear infection.
Molecular genotyping techniques such as MLST have
resulted in more accurate discrimination of strains thus
allowing us to determine whether these recurrent infec-
Table 1: Antibiotic susceptibility patterns of S. pneumoniae serotype 14 used in this study.
E-Test MIC μg/ml
Source Episode Penicillin G Chloramphenicol Tetracycline Cotrimoxazole Cefotaxime Erythromycin
Venous blood Second 0.19 2 32 8 0.25 0.064
Cerebrospinal fluid Second 0.19 1.5 24 6 0.25 0.125
Venous blood First 0.016 2 0.19 6 0.032 0.125Annals of Clinical Microbiology and Antimicrobials 2009, 8:3 http://www.ann-clinmicrob.com/content/8/1/3
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tions are due to relapse or new infection. Our data dem-
onstrate that the recurrent meningitis in this patient was
due to new infection rather than to relapse. Importantly
neither serological profile nor antibiotic susceptibility
data were reliable predictors of strain difference or iden-
tity. Unrelated strains sometimes have the same or similar
serological profiles while the same strains may have differ-
ences in either serological or antibiotic susceptibility. Typ-
ing of pneumococcal isolates by MLST is currently the
only reliable means of distinguishing relapse from new
infection, although other molecular-based methods may
also be sufficiently discriminatory.
Recurrent systemic pneumococcal infection is known to
occur in immunocompromised patients and patients with
underlying conditions such as sickle-cell disease, asplenia,
HIV, intracranial structural abnormalities or immununo-
logical abnormalities [12-15]. Unfortunately, we were not
able to investigate any underlying conditions in this child.
Conclusion
To our knowledge this is the first report describing the
exogenous re-infection of serotype 14 pneumococcal dis-
ease as the cause of meningitis from The Gambia. The
prominence of exogenous re-infection over relapse in this
patient with meningitis shows that current therapy for
meningitis in The Gambia is effective. However, this case
re-emphasizes the need for prevention of invasive pneu-
mococcal disease through routine conjugate pneumococ-
cal vaccination, which has yet to be introduced anywhere
in Africa. In addition, molecular genotyping of bacterial
isolates is critical to understand recurrent infections in
patients with meningitis.
Consent
Consent was obtained from the patient's parents to report
the case, which was identified through meningitis surveil-
lance approved by The Gambian Government/MRC ethics
committee
Dendrogram showing the relatedness by BOX-PCR profile among the STs of S. pneumoniae serotype 14 used in this study Figure 1
Dendrogram showing the relatedness by BOX-PCR profile among the STs of S. pneumoniae serotype 14 used 
in this study.
Minimum spanning tree constructed using STs from the ST63 and ST3321 clonal complexes [3] including those identified in this  study Figure 2
Minimum spanning tree constructed using STs from the ST63 and ST3321 clonal complexes [3]including those 
identified in this study. Each circle represents an ST. The area of each circle corresponds to the number of isolates. Thick, 
short, solid lines connect single-locus variants and thin, longer, solid lines connect double-locus variants. Unshaded (white) por-
tions represent previously described Gambian STs and shaded (black) portion represents ST found in this study. Clonal com-
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